Connor, Clark & Lunn Investment Management (CC&L)
PGNX

Connor, Clark & Lunn Investment Management (CC&L)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,100
Closed -$62K – 932
2015
Q4 		$62K Buy
+10,100
New +$66.2K ﹤0.01% 779
2015
Q1 		– Sell
-24,300
Closed -$184K – 634
2014
Q4 		$184K Buy
+24,300
New +$145K ﹤0.01% 532

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PGNX Position: Q1 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2016, closing a stake of 10,100 shares — an estimated $62K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PGNX in Q4 2014 and held it in 2 quarters. The position peaked at $184K in Q4 2014. 120 funds tracked by Wall St. Rank hold PGNX as of Q1 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 10,100 Progenics Pharmaceuticals Inc shares in Q1 2016, an estimated $62K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Progenics Pharmaceuticals Inc position peaked at $184K in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2016, filed 13 May 2016.